NAD+

NAD+: What It Is, How It Works & Where to Order in the UK (2026)

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every human cell that shuttles electrons in metabolism and acts as the obligate co-substrate for sirtuins, PARPs, and CD38 [1]. Cellular NAD+ declines with age. Three precursor routes now dominate the 2026 UK conversation: oral nicotinamide mononucleotide (NMN), oral nicotinamide riboside (NR), and intravenous NAD+ infusions offered through private clinics. This age-related decline happens because CD38 expression rises over time and NAMPT-mediated salvage activity falls, both of which reduce the NAD+ pool available for sirtuin and PARP function [1].

The regulatory picture matters before any biology does. NR is an authorised novel food in Great Britain and sits legally on supplement shelves; NMN remains an unauthorised novel ingredient with no FSA approval as of 2026; IV NAD+ is delivered off-label by private providers with no peer-reviewed UK outcomes data published. This article maps each route's mechanism, human-trial evidence, and current UK status side by side.

All Body Pharm NAD+ precursor compounds on JCSG.org are supplied for research purposes only. Not for human consumption.

Key Takeaways

• NAD+ is a coenzyme that declines with age, driving reduced sirtuin activity and linked to metabolic and mitochondrial dysfunction.
• Oral NR is legally authorised in the UK; NMN remains unauthorised; IV NAD+ is unlicensed and evidence-light.
• Human trials show reliable NAD+ elevation at standard doses but lack large RCTs proving clinical benefit for fatigue, cognition, or muscle function.
• Long-term safety data for high-dose NMN and NR supplementation in healthy adults do not yet exist.
• IV NAD+ infusions carry standard IV risks (infection, phlebitis) with no standardised dosing or outcome monitoring across UK clinics.
• JCSG.org stocks Body Pharm research-grade NAD+ precursors — order now via the UK peptide catalogue.

What Is NAD+? A Plain-Language Definition

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell that accepts and donates electrons during metabolism and is a consumable substrate for enzymes including sirtuins, PARPs, and CD38 [1][4]. It is not a vitamin, not a hormone, and not a peptide. It is a small dinucleotide built from nicotinamide and adenine joined through two ribose sugars and a phosphate bridge. That structure allows the nicotinamide ring to accept and release hydride ions — the chemical basis for its electron-shuttling role [1].

Lay coverage frequently blurs four related molecules that behave very differently. The distinctions matter:

• NAD+ — the oxidised form; accepts electrons in catabolism (glycolysis, the citric acid cycle, fatty-acid oxidation) and is consumed by sirtuins and CD38 [1][4].
• NADH — the reduced form of NAD+; carries electrons to the mitochondrial electron transport chain to drive ATP synthesis [4].
• NADP+ — NAD+ with an extra phosphate group; used in anabolic and antioxidant chemistry rather than energy extraction.
• NADPH — the reduced form of NADP+; supplies reducing power for lipid and nucleotide synthesis and regenerates glutathione.

The "+" is not decoration. It denotes the oxidation state of the nicotinamide ring: NAD+ has a positively charged nitrogen that can accept a hydride ion to become NADH. When a supplement label, clinic page, or news article says "NAD" without a sign, it usually refers to the NAD+/NADH pool collectively, which is imprecise but rarely consequential for a consumer. For mechanism discussions, sirtuin activity and CD38 hydrolysis specifically consume NAD+, not NADH or NADP+ [4].

For readers tracing how these cofactor structures inform drug design, see our work on the route from protein structures to peptide therapeutics, and our full peptides reference library for adjacent compounds.

The NAD+/NADH Redox Cycle Explained

NAD+ is the cell's principal electron shuttle because its nicotinamide ring can accept a hydride ion (two electrons plus a proton) to become NADH, then hand those electrons off downstream to regenerate NAD+. This back-and-forth, repeated millions of times per cell per second, links food oxidation to ATP synthesis [1]. The cycle is necessary because cells cannot store energy as free electrons. They must package it into the NAD+/NADH pair and pass it along a chain of carriers until the final electron acceptor — oxygen — is reached [1].

Three catabolic stages depend on this cycling. Glycolysis, in the cytosol, reduces two NAD+ to two NADH per glucose as glyceraldehyde-3-phosphate is oxidised. The tricarboxylic acid (TCA) cycle, in the mitochondrial matrix, generates a further three NADH per acetyl-CoA at the isocitrate, α-ketoglutarate, and malate dehydrogenase steps. Oxidative phosphorylation then uses Complex I of the electron transport chain to strip electrons from NADH, pump protons across the inner mitochondrial membrane, and ultimately drive ATP synthase. The reduction of NAD+ is required to maintain energy balance, as Covarrubias and colleagues set out in their 2020 Nature Metabolism review [1].

Why the NAD+/NADH ratio matters

The absolute amount of NAD+ in a cell is less informative than the NAD+/NADH ratio, because that ratio is the signal sensed by dehydrogenases, sirtuins, and metabolic regulators. A high cytosolic NAD+/NADH ratio (roughly 700:1 in healthy human cells) indicates spare oxidising capacity and permits continued glycolytic flux. A collapsed ratio signals reductive stress and stalls catabolism [1]. Dehydrogenases have different affinities for NAD+ and NADH, so they respond to shifts in the ratio rather than absolute concentrations [1]. Sirtuins, which consume NAD+ stoichiometrically when they deacylate target proteins, are effectively reading this ratio as a fuel gauge [1].

NAD+ versus NADP+: catabolism versus biosynthesis

NADP+ is NAD+ with a phosphate group added to the 2′-hydroxyl of the adenine ribose. That single modification routes it to an entirely different chemistry. NADPH (the reduced form) supplies reducing equivalents for fatty-acid and cholesterol synthesis, nucleotide biosynthesis, and the regeneration of reduced glutathione for antioxidant defence. NAD+/NADH cycles pull electronsout of fuel; NADP+/NADPH cycles push electrons into building blocks and redox buffering [1]. Confusing the two pools is the most common error in lay NAD+ writing. Supplementing precursors raises the NAD+/NADH pool specifically, not the NADPH available for biosynthesis — which is why claims about NAD+ supplementation improving antioxidant defences deserve scepticism, since that function depends on NADPH, not NAD+ [1].

For readers interested in how these cofactor-binding sites inform drug design, see our work on the route from protein structures to peptide therapeutics.

NAD+ and Sirtuins: The Ageing Connection

Sirtuins are NAD+-dependent deacylase enzymes (SIRT1–SIRT7) that consume NAD+ stoichiometrically as a co-substrate rather than recycling it as a cofactor. Every deacylation reaction permanently spends one NAD+ molecule and releases nicotinamide. That stoichiometric consumption is the mechanistic basis for linking declining cellular NAD+ pools to falling sirtuin activity, and in turn to the age-associated phenotypes that dominate longevity research [5]. Because sirtuins are rate-limited by NAD+ availability, tissues with falling NAD+ levels experience reduced sirtuin throughput even if the enzyme itself is unchanged [5].

What each sirtuin actually does

SIRT1 and SIRT3 are the most-studied isoforms in ageing contexts [5]. SIRT1 sits in the nucleus and cytoplasm, where it deacetylates transcription factors including p53, FOXO3, and PGC-1α, modulating gene expression programmes tied to DNA repair, inflammation, and metabolic adaptation. SIRT3 is the principal mitochondrial deacetylase and regulates oxidative phosphorylation efficiency, fatty-acid oxidation, and the antioxidant response via SOD2. SIRT6, nuclear and chromatin-associated, contributes to telomere maintenance, base-excision DNA repair, and glycolytic suppression. The remaining isoforms (SIRT2, SIRT4, SIRT5, SIRT7) cover cytoskeletal, ribosomal, and additional mitochondrial substrates, with smaller evidence bases in ageing specifically.

The mechanistic model, and its limits

The prevailing model runs as follows: NAD+ concentrations fall with age, driven partly by rising CD38 hydrolase activity and partly by reduced NAMPT-mediated salvage. Sirtuins become substrate-limited. Deacylation of their protein targets slows. Downstream programmes covering mitochondrial biogenesis, genome stability, and metabolic flexibility degrade [5]. Restoring NAD+ via precursors should, on this logic, restore sirtuin throughput and reverse age-related decline in these programmes. The preclinical support is substantial in rodents and invertebrates, with lifespan extension observed in multiple model organisms. Human RCT evidence that precursor supplementation actually rescues sirtuin-dependent endpoints — rather than simply raising blood NAD+ — remains thin as of 2026. Most trials report biochemical or short-term functional surrogates rather than hard ageing outcomes [4]. Animal findings on lifespan extension should not be presented as established human outcomes; the translation from rodent models to human longevity is unproven [5].

For the structural biology behind why NAD+ binds the sirtuin catalytic core in a conserved Rossmann-like fold, and why that geometry constrains inhibitor and activator design, see our note on the path from protein structures to peptide therapeutics. Readers tracking adjacent longevity compounds can also consult our full peptides reference library.

How the Body Makes NAD+: Biosynthesis and the NAMPT Salvage Pathway

The body produces NAD+ through three biosynthetic routes. More than 85% of daily turnover in most adult tissues is recycled through the salvage pathway rather than synthesised from scratch [1]. Understanding which route dominates, and why it falters, is what makes the supplementation rationale legible rather than mystical.

The first route is de novo synthesis from tryptophan via the kynurenine pathway. This is an eight-step sequence that ultimately feeds into quinolinic acid and then nicotinic acid mononucleotide (NaMN). It is metabolically expensive and contributes only a small fraction of the steady-state NAD+ pool in most peripheral tissues. The liver does most of the heavy lifting [1]. The second route is the Preiss–Handler pathway, which converts dietary nicotinic acid (niacin, vitamin B3) into NaMN via nicotinic acid phosphoribosyltransferase (NAPRT), then onward to NaAD and NAD+. This is the classical pellagra-prevention pathway and remains relevant wherever niacin intake is adequate.

The third route, the salvage pathway, recycles nicotinamide (NAM) released as a by-product whenever sirtuins, PARPs, or CD38 cleave NAD+ during their catalytic cycles. NAM is converted to NMN by nicotinamide phosphoribosyltransferase (NAMPT). NMN is then adenylylated to NAD+ by NMNAT enzymes. Because every sirtuin deacylation and every PARP-mediated DNA repair event consumes one NAD+ and releases one NAM, the salvage loop is the only route that can keep pace with continuous intracellular demand [1]. It is the fastest and most efficient route under normal metabolic conditions [1].

Why NAMPT is the bottleneck

NAMPT is the rate-limiting enzyme of the salvage pathway. Its catalytic step (NAM + PRPP → NMN) sets the ceiling on how fast nicotinamide can re-enter the NAD+ pool [1]. When NAMPT activity falls, salvage flux falls with it, and intracellular NAD+ drops even if dietary B3 intake is unchanged. Two factors press on NAMPT with age. First, intracellular NAMPT (iNAMPT) expression declines in multiple tissues including adipose, skeletal muscle, and liver — documented in rodent ageing models and inferred in human tissue from cross-sectional sampling [1]. Second, chronic low-grade inflammation, the so-called inflammaging phenotype, alters the iNAMPT/eNAMPT balance and is associated with reduced effective salvage capacity at the cellular level [1]. This inflammaging-driven reduction in NAMPT activity is one proposed mechanism linking systemic inflammation to tissue NAD+ decline [1].

This is why precursor strategies targeting downstream of NAMPT (NMN, NR) are theoretically attractive: they bypass the bottleneck and restore NAD+ even if NAMPT activity is impaired. Whether that bypass translates to functional benefit in humans is the question the next sections address. Readers tracking enzyme-targeted approaches more broadly can consult our full peptides reference library for adjacent mechanisms.

NMN vs NR vs IV Infusion: A 2026 Comparison

Oral NAD+ itself is poorly bioavailable because the gut degrades it before it reaches systemic circulation. Every viable strategy uses a precursor (NMN, NR, niacin) or bypasses the gut entirely (IV). The table below maps each route against mechanism, evidence quality, and current UK regulatory standing as of 2026.

NMN

NMN is the most-discussed precursor and the most regulatorily unsettled. Trials published before 2023 (and still cited through 2026) show reliable NAD+ elevation at trial doses, with mostly neutral or modestly positive functional readouts such as walking speed and insulin sensitivity [3][6]. The US FDA's 2023 exclusion of NMN from the dietary supplement definition does not apply in the UK, but FSA novel food status here is not resolved. Check current FSA guidance before purchasing. JCSG.org stocks Body Pharm research-grade NMN — see the current UK catalogue for availability.

NR

NR has the cleanest UK regulatory position of the three precursors: it sits on the authorised novel foods list as a permitted food supplement ingredient, with dose caps and purity specifications. Human trials at various doses report mild, reversible adverse events (gastrointestinal upset, occasional headache) and consistent NAD+ elevation [6]. What is still missing across the NR literature, as of 2026, is any large RCT measuring hard outcomes such as frailty progression or cardiovascular events. NR is safe and bioavailable; its clinical utility for ageing-related conditions is not yet proven [6].

IV NAD+ infusion

IV NAD+ is the route with the loudest marketing and the thinnest evidence. UK private providers describe protocols of varying doses per session over several hours, with claims around energy and cognitive clarity. Published outcomes are anecdotal rather than controlled [5][6]. The MHRA has not issued a specific safety alert dedicated to IV NAD+ as of 2026, though general IV-drip cautions (phlebitis, infection, unlicensed claims) apply. Treat it as an unlicensed wellness intervention. Without standardised dosing protocols and outcome monitoring across UK clinics, safety and efficacy data cannot be aggregated or compared.

Niacin

Niacin is the original NAD+ precursor and the only one with large RCT data, though those trials targeted lipid and cardiovascular endpoints rather than NAD+ pharmacology. Flushing at gram-scale doses limits tolerability, and it is rarely framed as a longevity intervention in 2026 commentary. Its long history of use and extensive safety data make it a lower-risk option than newer precursors, though its cardiovascular benefits do not translate directly to ageing outcomes.

For readers tracking how NAD+-dependent enzyme structures inform inhibitor and modulator design, from protein structures to peptide therapeutics covers the structural-biology side; adjacent compound classes are catalogued in our full peptides reference library.

NAD+ Benefits: What the Human Evidence Shows in 2026

Human evidence for NAD+ precursor supplementation in 2026 is consistent on one point and inconclusive on most others: oral NMN and NR reliably raise blood NAD+ by roughly 30–100% from baseline at trial doses. No large Phase III RCT has established any NAD+ precursor as a licensed treatment for fatigue, metabolic disease, cognitive decline, or sarcopenia [6]. Everything below should be read against that ceiling. Raising a biomarker is not the same as improving a clinical outcome, and NAD+ elevation is necessary but not sufficient to establish therapeutic benefit [6].

Energy and fatigue

Small RCTs of NR and NMN over 6–12 weeks report modest, subjective improvements in self-rated energy and reductions in perceived fatigue, alongside biochemical NAD+ elevation [6]. Effect sizes are small, blinding quality varies, and no replicated RCT has shown a clinically meaningful change on a validated fatigue scale as a primary endpoint. The improvements observed are typically in the range of 10–20% above placebo, below the threshold for clinical significance in fatigue trials. Anyone concerned about fatigue should first consult a GP to rule out anaemia, thyroid dysfunction, or sleep disorders before considering NAD+ supplementation.

Metabolic health

The strongest signal sits here, and it is still modest. A 2021–2022 Japanese trial in older adults and several overweight-adult cohorts reported improvements in insulin sensitivity and muscle insulin signalling with NMN at trial doses, alongside neutral effects on body composition and lipids. Covarrubias and colleagues (2020) framed the mechanistic rationale linking NAD+ decline to metabolic disease. That hypothesis has not been confirmed in a large 2024–2026 RCT with hard endpoints such as HbA1c trajectories or progression to type 2 diabetes. The metabolic improvements observed in smaller trials may reflect short-term changes in insulin signalling rather than sustained metabolic remodelling. Anyone with type 2 diabetes or prediabetes should discuss NAD+ supplementation with their GP or diabetes specialist before starting, as the interaction with existing medications is unknown.

Cognitive function

Cognitive trials are early-stage. Pilot studies in healthy older adults using NR have measured processing speed, working memory, and cerebrospinal fluid (CSF) NAD+ markers, with mixed and largely null results on cognitive endpoints despite measurable peripheral NAD+ rises [6]. No published 2024–2026 trial supports a cognitive indication. The failure of NAD+ elevation to translate to cognitive gains in these early trials suggests that peripheral NAD+ changes may not reach the brain in sufficient quantity, or that cognitive ageing involves NAD+-independent mechanisms.

Muscle function and exercise

Results are mixed. Some NR and NMN trials in older or overweight adults show small gains in gait speed or grip strength. Others report no change in VO₂max, time-to-exhaustion, or muscle protein synthesis despite NAD+ elevation. The field lacks an adequately powered RCT in frailty or sarcopenia with falls or disability as the primary outcome. The inconsistency across trials likely reflects differences in baseline fitness, age, and comorbidity, all of which are known to modify exercise responses. Readers with sarcopenia or mobility concerns should prioritise resistance training and adequate protein intake, which have stronger evidence bases than NAD+ supplementation.

For readers tracking how NAD+-dependent enzymes intersect with drug design, see our full peptides reference library for adjacent compound classes and trial maturity.

NAD+ Side Effects and Safety Considerations

Oral NMN and NR are reported as generally well tolerated in published human trials up to 6–12 months, with adverse events typically limited to mild nausea, flushing, headache, and transient gastrointestinal discomfort [6]. This section is informational and does not constitute medical advice. Anyone considering NAD+ precursors or infusions should consult a GP or appropriately qualified clinician, particularly if pregnant, breastfeeding, on prescription medication, or living with cancer, liver, or kidney disease [6]. The reason for this caution is that NAD+-dependent enzymes are involved in DNA repair and cell-cycle control, and NAD+ supplementation could theoretically affect cancer risk or progression, though this has not been studied systematically in humans.

Oral precursors: what trials have actually captured

No 2025–2026 RCT has reported dose-limiting toxicities or serious unexpected reactions at the dose ranges studied to date. Reviewers summarising more than 70 human studies describe the short-to-medium-term safety profile as acceptable in adults without major comorbidity [6]. I have deliberately not restated specific milligram thresholds in this safety paragraph, because trial-specific dose tolerability differs by formulation and population. Readers needing a precise figure should consult the most recent primary trial relevant to their age and health status. Long-term cancer, cardiovascular, and mortality data for high-dose NMN or NR in humans are not yet available as of 2026 [6]. That absence is a significant limitation when considering supplementation in healthy individuals, since the risk-benefit calculus depends on knowing whether NAD+ elevation carries any long-term harms.

IV NAD+ infusions in UK private clinics

IV NAD+ carries a distinct risk profile: any intravenous route introduces infection, phlebitis, and extravasation risks. UK private providers publish only promotional and anecdotal accounts rather than controlled outcome or adverse-event datasets [4][5]. Dosing protocols, infusion rates, and patient-selection criteria are not standardised across UK clinics, and no MHRA-issued practice guideline exists specifically for IV NAD+ as of 2026. Without standardisation, safety monitoring is inconsistent, and serious adverse events may not be reported or aggregated.

For adjacent compound classes where structural and safety data are similarly evolving, see our full peptides reference library.

UK Regulatory Status of NAD+ Supplements and Infusions (2026)

In the UK, oral NR is a legally marketable food supplement ingredient under existing FSA novel food authorisation. Oral NMN sits in an unauthorised grey area pending any successful novel food application. IV NAD+ infusions are unlicensed therapies offered only through private clinics outside the NHS. None of these products is an MHRA-licensed medicine, and none can lawfully carry disease-treatment or disease-prevention claims. The regulatory framework reflects the distinction between food supplements (which require safety and efficacy data but not clinical trial evidence) and medicines (which require licensed clinical trials and marketing authorisation).

How MHRA and FSA divide the territory

The MHRA regulates products presented as medicines, including any compound making a medicinal claim or supplied by injection for a therapeutic indication. The FSA regulates food supplements, including novel foods that were not consumed to a significant degree in the UK before 1 May 1997. Oral NAD+ precursors fall to the FSA unless a seller makes medicinal claims, at which point MHRA enforcement can follow. A product's regulatory status therefore depends partly on how it is marketed, not just its chemical composition.

NR vs NMN: a sharp legal asymmetry

Nicotinamide riboside has held novel food authorisation in Great Britain and the EU since before 2023, with conditions on intended population, maximum daily dose, and purity. That authorisation remains in force in 2026. NMN does not appear on the FSA's authorised novel foods list as of 2026, so UK-based businesses cannot lawfully place NMN food supplements on the market without a granted application. This asymmetry reflects the timing of regulatory submissions and the FDA's 2023 decision to exclude NMN from the dietary supplement definition in the US, which has discouraged UK applications.

IV NAD+: unlicensed, clinic-administered

NAD+ injections are unlicensed therapies, consistent with the absence of any MHRA marketing authorisation for IV NAD+ as of 2026. Private providers may still administer it under standard prescribing and clinical-governance frameworks, but it is not an NHS-approved treatment. The legal basis for private IV NAD+ administration rests on the principle that a qualified clinician can prescribe an unlicensed medicine off-label. That does not mean the therapy is evidence-based or safe.

Contrast with the US

The US FDA's 2023 position excluding NMN from the dietary supplement definition (because it was first investigated as a drug) remains in force in 2026 and has driven US brands to reformulate or sell overseas. It has no direct legal effect in the UK, where FSA novel food rules govern instead. Products available in the US may therefore not be available in the UK, and vice versa.

UK Regulatory Note (flag for legal review before publication): NMN's UK status is evolving and depends on any pending FSA novel food decisions. Verify the current Union list entry and any MHRA position statements at the date of publication. Nothing in this section is legal advice.

For readers tracing how regulatory pathways shape adjacent compound classes, see our full peptides reference library, and for the structural-biology bridge to drug design, from protein structures to peptide therapeutics.

NAD+ in Structural Biology and Peptide Research

NAD+ is both a redox cofactor and a structural ligand recognised by a conserved Rossmann-like fold present across hundreds of dehydrogenases, sirtuins, and ADP-ribosyl transferases [1]. That fold — a βαβαβ motif binding the dinucleotide in an extended conformation — is one of the most thoroughly catalogued ligand-binding architectures in the PDB. This is why NAD+-dependent enzymes featured heavily in early structural genomics target lists, including work at the Joint Center for Structural Genomics. The conservation of this fold across such diverse enzyme families reflects the antiquity of NAD+ as a cofactor and the evolutionary pressure to maintain a binding pocket that can accommodate the dinucleotide [1].

Three enzyme families dominate the therapeutic conversation. Sirtuins (SIRT1–7) are NAD+-dependent deacylases whose catalytic cores cleave the nicotinamide–ribose bond during substrate turnover, consuming one NAD+ per deacylation event [1]. PARPs use NAD+ as the donor for poly-ADP-ribosylation during DNA damage response. CD38 is an NAD+ glycohydrolase whose rising expression with age is one proposed driver of tissue NAD+ decline [1]. Each presents a structurally distinct active site, and each is now a target for small-molecule inhibitors and, increasingly, peptide-based modulators. The structural differences between these active sites explain why a single inhibitor cannot block all three families simultaneously [1].

Why this matters for peptide design

Resolving how NAD+ docks into these active sites tells designers exactly where a competitive peptide must sit, which side chains to mimic, and which sub-pockets tolerate substitution. CD38 inhibitor development in particular has drawn on iterative crystallographic refinement of inhibitor-bound complexes through 2024–2026. For the structural-biology-to-therapeutic pipeline that frames this work, see from protein structures to peptide therapeutics, and for the wider compound context, our full peptides reference library.

Read this way, NAD+ is less a "supplement molecule" than a recurrent structural motif whose binding pockets define a large slice of the druggable proteome. Understanding NAD+ biochemistry is therefore necessary for anyone designing inhibitors or modulators of sirtuins, PARPs, or CD38 [1].

Frequently Asked Questions About NAD+

What is the difference between NAD+ and NADH?

NAD+ is the oxidised form of nicotinamide adenine dinucleotide and NADH is its reduced form. The pair shuttle electrons during cellular respiration. NAD+ accepts a hydride ion at complex I substrates to become NADH, which then donates electrons to the electron transport chain. The NAD+/NADH ratio, not absolute NAD+, drives most redox-sensitive signalling [1]. That ratio is what cells actually sense and respond to, which is why raising total NAD+ without changing the ratio may not produce the expected metabolic effects [1].

Does NAD+ decline with age?

Tissue NAD+ levels fall with age in human and animal studies, with rising CD38 expression cited as a principal driver alongside reduced NAMPT salvage activity [1]. 2024–2026 reviews consistently describe this trajectory, though the magnitude varies by tissue and the causal link to age-related disease in humans remains an active research question [4][6]. The decline is most pronounced in tissues with high metabolic demand, such as muscle and liver, and less evident in tissues with lower turnover.

Can you take NAD+ as a supplement?

Oral NAD+ itself is poorly bioavailable, so commercial products supply precursors, principally NMN, NR, or niacin, which the salvage pathway converts intracellularly. UK clinics also offer intravenous NAD+ infusions that bypass gut absorption [1][3]. The choice of precursor matters because each has different bioavailability, regulatory status, and evidence base. JCSG.org stocks research-grade Body Pharm NAD+ precursors — see the UK peptide catalogue for current availability.

Is NMN legal in the UK?

NMN is treated as an unauthorised novel food in the UK as of 2026, with no FSA Union list entry permitting its sale as a food supplement ingredient. This contrasts with the US, where the FDA's 2023 exclusion of NMN from the dietary supplement definition remains in force. The legal status may change if an application is submitted and approved by the FSA.

What is the difference between NMN and NR?

NMN (nicotinamide mononucleotide) sits one enzymatic step closer to NAD+ than NR (nicotinamide riboside) in the salvage pathway. NR is authorised as a novel food ingredient in Great Britain with defined dose caps; NMN is not. NMN's closer proximity to NAD+ means it requires fewer enzymatic steps to be converted, though this theoretical advantage has not translated to superior clinical outcomes in human trials.

Are NAD+ IV infusions safe in the UK?

UK private clinics offer IV NAD+ but have published no controlled outcomes data. As of 2026 the MHRA has issued no specific guidance on the practice [1]. Risks flagged in general IV-drip guidance include phlebitis, infection, and inappropriate medical claims. The absence of standardised protocols and outcome monitoring means that safety cannot be assured.

Order Body Pharm NAD+ Precursors on JCSG.org

JCSG.org is the UK destination for Body Pharm research compounds. Whether you are sourcing NMN, NR, or related NAD+ precursors for in vitro or laboratory research, the current stock and live pricing are available in the buy box above. No third-party markups, no grey-import supply chains — order direct through JCSG.org today.

• Browse all Body Pharm peptides and research compounds available in the UK
• Go to cart and complete your order

Questions about a specific compound? See the individual product pages linked from the UK peptide catalogue for full technical specifications, purity data, and current pricing.